INTERNATIONAL PATENT: JANSSEN PHARMACEUTICA NV, JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. FILES APPLICATION FOR "(R) -N-ETHYL-5-FLUORO-N-ISOPROPYL-2- ( (5- (2- (6- ( (2-METHOXYETHYL) (METHYL) AMINO) -2-METHYLHEXAN-3-YL) -2, 6-DIAZASPIRO [3.4] OCTAN-6-YL) -1, 2, 4-TRIAZIN-6-YL) OXY) BENZAMIDE, FORMULATIONS AND DOSAGE REGIMENS THEREOF, FOR USE IN TREATING CANCER"

GENEVA, April 30 -- JANSSEN PHARMACEUTICA NV (Turnhoutseweg 30, Beerse2340), JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (2101, No. 1 Building, 65 Gui Qing RoadXuhui District, Shanghai 200233) filed a patent application (PCT/CN2024/125527) for "(R) -N-ETHYL-5-FLUORO-N-ISOPROPYL-2- ( (5- (2- (6- ( (2-METHOXYETHYL) (METHYL) AMINO) -2-METHYLHEXAN-3-YL) -2, 6-DIAZASPIRO [3.4] OCTAN-6-YL) -1, 2, 4-TRIAZIN-6-YL) OXY) BENZAMIDE, FORMULATIONS AND DOSAGE REGIMENS THEREOF, FOR USE IN TREATING CANCER" on Oct 17, 2024. With publication no. WO/2025/082444, the details related to the patent application was published on Apr 24, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed b...